10X Genomics


10x Genomics, Inc. is an American company incorporated in 2012 that develops and manufactures integrated systems for whole genome sequencing, exome sequencing and single cell transcriptomics. Its headquarters are located in Pleasanton, California.


10X Genomics Company Profile  


President & CEO: Serge Saxonov

CEO photo:

 10X Genomics CEO photo - Serge Saxonov

Website: http://10xgenomics.com

Headquarters: Pleasanton, CA

10x Genomics employees: 101-250

Funding: $113M USD

Founded: 2012

Founders: Serge Saxonov, Ben Hindson


10x Genomics News 

Inscripta is creating its own market and customer base while also utilizing the expertise of its customers to refine and improve its products.

The company plans to launch a single-cell CNV assay, a single cell ATAC-seq assay, and a single-cell feature barcoding assay later this year.

An Australian team used Pacific Biosciences long reads, 10X Genomics linked reads, and Bionano Genomics mapping to assemble a desert dingo genome de novo.

Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.

The companies will work together on a new sequencing-based NIPT technology developed by 10x Genomics for the Chinese market.

The combined workflow will enable the analysis of archival dried blood spots using 10x Genomics' linked-read technology, according to the companies.

Bio-Rad claims that 10x Genomics infringes on patents it holds related to emulsion formation in microfluidics chips. 

The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology. 

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.

The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.